CNBX Pharmaceuticals Inc. (CNBX) stock
CNBXOTCPharmaceutical PreparationsFiscal year ends August 31
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $197.79KP/E –Yield –
CNBX Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CNBX Pharmaceuticals's operating income for the twelve months ending May 31, 2026 was -$429.46K. For fiscal 2025 it was -$271.69K. The highest annual figure on record is -$58.11K in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | -$271.69K | – |
| FY2024 | Aug 31, 2024 | -$583.14K | – |
| FY2023 | Aug 31, 2023 | -$931.38K | – |
| FY2022 | Aug 31, 2022 | -$2.95M | – |
| FY2021 | Aug 31, 2021 | -$2.60M | – |
| FY2020 | Aug 31, 2020 | -$3.04M | – |
| FY2019 | Aug 31, 2019 | -$3.30M | – |
| FY2018 | Aug 31, 2018 | -$3.81M | – |
| FY2017 | Aug 31, 2017 | -$1.85M | – |
| FY2016 | Aug 31, 2016 | -$280.68K | – |
| FY2015 | Aug 31, 2015 | -$536.50K | – |
| FY2014 | Aug 31, 2014 | -$216.13K | – |
| FY2013 | Aug 31, 2013 | -$58.11K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | -$162.76K | – |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | -$72.96K | – |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | -$64.00K | – |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | -$129.73K | – |
| Q3 FY2025CQ2 2025 | May 31, 2025 | -$40.38K | – |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | -$64.74K | – |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | -$36.84K | – |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | -$52.53K | – |
| Q3 FY2024CQ2 2024 | May 31, 2024 | -$152.28K | – |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | -$206.43K | – |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | -$171.90K | – |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | -$161.50K | – |
| Q3 FY2023CQ2 2023 | May 31, 2023 | -$173.08K | – |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | -$250.01K | – |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | -$346.79K | – |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | -$478.35K | – |
| Q3 FY2022CQ2 2022 | May 31, 2022 | -$635.01K | – |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | -$730.26K | – |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | -$1.11M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$596.32K | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$676.25K | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$667.87K | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$659.73K | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$670.71K | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$690.51K | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$866.37K | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$815.86K | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$979.75K | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$779.52K | – |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -$896.05K | – |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -$648.29K | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$718.57K | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$851.76K | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$1.70M | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$536.95K | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$1.09M | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$472.88K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$192.55K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$102.88K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$66.60K | – |
See a number that looks wrong?